REFERENCES
- Robert J Motzer, Bernard Escudier, Stéphane Oudard, Thomas E Hutson,
Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A Thompson,
Robert A Figlin, Norbert Hollaender, Gladys Urbanowitz, William J
Berg, Andrea Kay, David Lebwohl, Alain Ravaud, RECORD-1 Study Group.
Efficacy of everolimus in advanced renal cell carcinoma: a
double-blind, randomised, placebo-controlled phase III trial. Lancet
2008 Aug 9;372(9637):449-56..
- James
C Yao,
Manisha
H Shah,
Tetsuhide
Ito,
Catherine
Lombard Bohas,
Edward
M Wolin,
Eric
Van Cutsem,
Timothy
J Hobday,
Takuji
Okusaka,
Jaume
Capdevila,
Elisabeth
G E de Vries,
Paola
Tomassetti,
Marianne
E Pavel,
Sakina
Hoosen,
Tomas
Haas,
Jeremie
Lincy,
David
Lebwohl,
Kjell
Öberg,
RAD001
in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study
Group. Everolimus for advanced pancreatic neuroendocrine tumors. N
Engl J Med 2011 Feb 10;364(6):514-23.
- Guy
Jerusalem,
Richard
H de Boer,
Sara
Hurvitz,
Denise
A Yardley,
Elena
Kovalenko,
Bent
Ejlertsen,
Sibel
Blau,
Mustafa
Özgüroglu,
László
Landherr,
Marianne
Ewertz,
Tetiana
Taran,
Jenna
Fan,
Florence
Noel-Baron,
Anne-Laure
Louveau,
Howard
Burris. Everolimus Plus Exemestane vs Everolimus or
Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative
Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. JAMA
Oncol 2018 Oct 1;4(10):1367-1374.
- Marc
I Lorber,Claudio
Ponticelli,
John
Whelchel,
Hartmut
W Mayer,
John
Kovarik,
Yulan
Li,
Heinz
Schmidli. Therapeutic drug monitoring for everolimus in kidney
transplantation using 12-month exposure, efficacy, and safety data.
Clin Transplant 2005 Apr;19(2):145-52..
- Maria
Shipkova,
Dennis
A Hesselink,
David
W Holt,
Eliane
M Billaud,
Teun
van Gelder,
Paweł
K Kunicki,
Mercè
Brunet,
Klemens
Budde,
Markus
J Barten,
Paolo
De Simone,
Eberhard
Wieland,
Olga
Millán López,
Satohiro
Masuda,
Christoph
Seger,
Nicolas
Picard,
Michael
Oellerich,
Loralie
J Langman,
Pierre
Wallemacq,
Raymond
G Morris,
Carol
Thompson,
Pierre
Marquet. Therapeutic Drug Monitoring of Everolimus: A Consensus
Report. 2016 Apr;38(2):143-69.
- Alain
Ravaud, Shweta R Urva , Kai Grosch, Wing K
Cheung, Oezlem Anak, Dalila B Sellami..Relationship
between everolimus exposure and safety and efficacy: meta-analysis of
clinical trials in oncology. Eur J Cancer 2014 Feb;50(3):486-95.
- John
M
Kovarik, Doris
Beyer, Robert
L Schmouder. Everolimus drug interactions: application of a
classification system for clinical decision making. Biopharm Drug
Dispos. 2006 Dec;27(9):421-6.
- Jennifer
A Grabowsky. Drug interactions and the pharmacist: focus on
everolimus. Ann Pharmacother. 2013 Jul-Aug;47(7-8):1055-63.
- Laura
Molenaar-Kuijsten, Dorieke E M Van
Balen, Jos
H
Beijnen,
Neeltje Steeghs, Alwin D R Huitema. A Review of CYP3A Drug-Drug
Interaction Studies: Practical Guidelines for Patients Using Targeted
Oral Anticancer Drugs. Front Pharmacol. 2021 Aug 30;12:670862.
- Sabrina
Falkowski, Jean-Baptiste
Woillard. Therapeutic Drug Monitoring of Everolimus in Oncology:
Evidences and Perspectives. Ther Drug Monit. 2019 Oct;41(5):568-574.
- W.
Cheung , C.
Ligia , A.
Jappe , O. Anak.
Pharmacokinetic (PK) profile of a single dose of everolimus (10 mg)
administered with a low- or high-fat meal and under fasting conditions
in healthy subjects. Meeting Abstract | 2011 ASCO Annual
Meeting I.
- Masaki
Hirabatake, Tomoyuki Mizuno, Hironori Kato, Tohru Hashida.Everolimus
pharmacokinetics and exposure-response relationship in Japanese
patients with advanced breast cancer. Eur J Clin Pharmacol. 2019
Sep;75(9):1309-1318.
- J
M
Kovarik, D
Beyer, M
N
Bizot, Q
Jiang, M
J
Allison, R
L Schmouder. Pharmacokinetic interaction between verapamil and
everolimus in healthy subjects. Br J Clin Pharmacol 2005
Oct;60(4):434-7.
- Geoffrey
Strobbe, Diane Pannier, Ilyes
Sakji, Alexandre
Villain, Frédéric Feutry, Guillaume Marliot. Advantages of everolimus
therapeutic drug monitoring in oncology when drug-drug interaction is
suspected: A case report. J Oncol Pharm Pract 2020
Oct;26(7):1743-1749.
- J
M
Kovarik, D
Beyer, M
N
Bizot, Q
Jiang, M
Shenouda, R
L Schmouder. Effect of multiple-dose erythromycin on everolimus
pharmacokinetics. Eur J Clin Pharmacol 2005 Mar;61(1):35-8.
- Andrew
R Miesner, Marissa
Ausman, Benjamin
Dagraedt, Joseph
Zieminski. Probable Drug Interaction Between Everolimus and
Clarithromycin. Ann Pharmacother 2016 Aug;50(8):689-90.
- P
N
Tran, L
C Pinter-Brown. Everolimus-induced nephrotic syndrome precipitated by
interaction with voriconazole in a patient with Hodgkin’s lymphoma. J
Clin Pharm Ther 2017 Dec;42(6):776-779.
- O
Mir, V
Poinsignon, M
Arnedos, S
Delaloge, A
Paci. Pharmacokinetic interaction involving fenofibrate and
everolimus. Ann Oncol 2015 Jan;26(1):248-249.
- Remy B. Verheijen, Florence Atrafi, Jan H.M. Schellens, Jos H.
Beijnen, Alwin D.R. Huitema, Ron H.J. Mathijssen, Neeltje Steeghs.
Pharmacokinetic optimization of everolimus dosing in oncology: a
randomized crossover trial. Clin Pharmacokinet, 2018, 57:637-644.